Preeclampsia diagnostics play a crucial role in the management and diagnosis of preeclampsia during pregnancy. Transcutaneous monitoring devices and biomarkers help identify preeclampsia symptoms at an early stage.
The global Preeclampsia Diagnostics Market is estimated to be valued at Us$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR Of 5.6% over the forecast period 2023 To 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising adoption of advanced diagnostic technologies is primarily driving the growth of the preeclampsia diagnostics market. Various novel technologies such as biomarker testing, imaging, and novel monitoring devices are aiding early detection of preeclampsia and contributing to the market growth. For instance, placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1) are some of the extensively studied biomarkers for preeclampsia diagnosis. Additionally, technological advancements in devices such as Doppler ultrasound and improved blood pressure cuffs enable pin-point accuracy for monitoring and diagnosis of preeclampsia. Furthermore, growing awareness regarding preeclampsia and increasing initiatives by key market players for the development of innovative diagnostic solutions are further accentuating the market growth.
Segment Analysis
The global preeclampsia diagnostics market is dominated by the blood pressure monitors segment. High blood pressure is one of the early signs of preeclampsia and regular monitoring is important for the early detection of this condition. Blood pressure monitors allow physicians to closely track any spikes in blood pressure and intervene timely if needed. This makes blood pressure monitors a crucial diagnostic tool for preeclampsia screening and management.
Key Takeaways
The Global Preeclampsia Diagnostics Market Demand is expected to witness high growth over the forecast period of 2023 to 2030. The global Preeclampsia Diagnostics Market is estimated to be valued at US$ 1587.53 Mn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030.
Regional analysis:
North America currently dominates the global market due to high awareness about preeclampsia diagnostics and availability of advanced treatments. However, Asia Pacific is expected to grow at the fastest pace due to rising healthcare expenditures and increasing patient pool in countries like China and India.
Key players:
Key players operating in the preeclampsia diagnostics market are AstraZeneca, CorMedix, Inc., Citus Pharmaceuticals, Fresenius Medical Care, Glenmark Pharmaceuticals Ltd., Geistlich Pharma, Merck & Co., Inc., Pfizer, TauroPhar GmbH, Xellia Pharmaceuticals Ltd.. These players are focusing on new product launches and partnerships to strengthen their market position.
Get more insights on this topic :
